Psychedelics & the Brain: How Drugs Trigger Dreamlike Hallucinations

The human brain’s capacity for internal experience is being illuminated by new research into the effects of psychedelic compounds. A study in mice, published in Communications Biology, suggests that psychedelics don’t necessarily *create* hallucinations, but rather shift the brain’s focus from external reality to internal memory, effectively allowing the brain to “dream while awake.” This finding builds on decades of research into how these substances interact with brain chemistry and could have implications for the development of new treatments for mental health conditions.

Researchers have long known that indigenous cultures utilized psychedelic substances for healing purposes. The Aztecs employed psilocybin mushrooms medicinally, while Andean communities used mescaline-containing cacti in rituals. Archaeological discoveries, including a 5,000-year-old bundle containing traces of DMT found in a Bolivian cave, demonstrate a deep historical connection between humans and these mind-altering plants. Archaeological evidence suggests these practices date back millennia.

Modern scientific investigation began in 1938 with Albert Hofmann’s synthesis of LSD. Subsequent research in the 1970s and 80s identified the 5-HT2A receptor as a key target for these drugs, linking their effects to the serotonin system, which plays a crucial role in mood regulation and conditions like anxiety, and depression. Understanding this receptor has been central to unraveling the mechanisms behind psychedelic experiences.

The Neuroplasticity Debate

Currently, scientists are debating whether the subjective “trip” experienced during psychedelic use is essential for therapeutic benefit. While the mystical experience itself may be impactful, a growing body of evidence suggests that the real power of psychedelics lies in their ability to promote neuroplasticity – the brain’s capacity to reorganize itself by forming new neural connections. This rewiring process could be the key to treating conditions like depression and PTSD, with hallucinations potentially being a byproduct of this deeper neurological shift.

The recent study, led by Dirk Jancke and colleagues at Ruhr University Bochum, Germany, used a novel approach to observe brain activity in mice. Researchers engineered mice with brain cells that glow when activated, allowing them to visualize neural activity with unprecedented clarity. They also developed technologies to record changes in voltage across the brain’s surface, providing a detailed picture of how different brain regions communicate.

During the experiment, mice were exposed to visual stimuli – moving black and white patterns and blank screens – while researchers monitored their brain activity. Halfway through, the mice received a chemical that selectively activates the 5-HT2A serotonin receptor, mimicking the effects of psychedelics like LSD and psilocybin. By comparing brain activity before and after drug administration, the researchers pinpointed the neural circuits most affected by the psychedelic compound.

Shifting Focus from External to Internal

The study revealed a significant shift in brain communication after the drug was administered. Before the psychedelic, the visual cortex exhibited 5-Hz brain oscillations, a pattern associated with processing external visual information. However, after the drug took effect, these oscillations intensified and synchronized with activity in the retrosplenial cortex, a brain region involved in memory encoding, storage, and retrieval. This synchronization occurred with a delay of approximately 18 milliseconds, suggesting a coordinated flow of activity between the two regions.

Crucially, the psychedelic appeared to dampen the brain’s response to external visual stimuli while simultaneously boosting connections with memory areas. This suggests that, under the influence of the drug, the brain began to prioritize internal imagery over external reality, effectively “filling in” missing visuals from memory. This finding offers a potential explanation for the visual hallucinations experienced during psychedelic states.

Jancke described this state as being akin to partial dreaming, where the brain’s internal imagery overrides external perception, creating a vivid, self-generated world. This isn’t about the brain malfunctioning, but rather a fundamental shift in how it processes information.

Limitations and Future Directions

While these findings are promising, the researchers acknowledge certain limitations. The study was conducted on mice, and it remains unclear whether the same mechanisms operate in the human brain. The repetitive nature of the visual stimuli used in the experiment could have contributed to the observed effects, as the mice may have grow distracted.

Despite these caveats, the study represents a crucial step toward developing new therapeutic approaches. The ultimate goal is to design drugs that can harness the neuroplastic benefits of psychedelics without inducing hallucinogenic effects. Researchers are increasingly focused on identifying compounds that can trigger therapeutic neuroplasticity without the unwanted side effects of a full psychedelic experience.

The research team is now planning further studies to investigate the long-term effects of these compounds on brain structure and function. They also hope to explore the potential of using non-invasive brain stimulation techniques to enhance neuroplasticity and treat mental health conditions. The ongoing investigation into the brain’s response to psychedelics promises to unlock new insights into the nature of consciousness and the potential for innovative mental health treatments.

What comes next: Clinical trials are underway to assess the efficacy of psilocybin and other psychedelic compounds for treating depression, anxiety, and PTSD. These trials will be crucial in determining whether the benefits observed in animal studies translate to humans and in identifying the optimal dosage and treatment protocols. Regulatory agencies will carefully review the data from these trials before considering approval for clinical use.